Precision Medicine in Oncology®

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Latest News

Anita Scheuber, MD, PhD
Adding an HPK1 Inhibitor to Immune Checkpoint Inhibition May Be Effective in Solid Tumors

November 22nd 2024

Anita Scheuber, MD, PhD, details how HPK1 inhibition may enhance the antitumor activity of ICIs in solid tumors, diving into the agent NDI-101150 in particular.

FDA
FDA Grants Fast Track Designation to ALE.P02 for CLDN1+ Squamous Solid Tumors

November 19th 2024

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

November 15th 2024

Repotrectinib Garners Positive CHMP Opinion for ROS1+ NSCLC and NTRK+ Solid Tumors
Repotrectinib Garners Positive CHMP Opinion for ROS1+ NSCLC and NTRK+ Solid Tumors

November 15th 2024

Revumenib in NPM1+ R/R AML | Image Credit: © LASZLO– stock.adobe.com
Revumenib Meets CR/CRh End Point in NPM1+ R/R AML

November 12th 2024

More News

Genomic Testing & Adjuvant Therapy in HR+ Breast Cancer

Genomic Testing & Adjuvant Therapy in HR+ Breast Cancer

March 29th 2019
CDK4/6 Inhibitors: Treating Beyond Progression

CDK4/6 Inhibitors: Treating Beyond Progression

March 29th 2019
Selecting a CDK4/6 Inhibitor in HR+ Breast Cancer

Selecting a CDK4/6 Inhibitor in HR+ Breast Cancer

March 29th 2019
Managing CDK4/6 Inhibitor Adverse Events

Managing CDK4/6 Inhibitor Adverse Events

March 29th 2019
CDK4/6 Inhibitor Toxicity in HR+ Breast Cancer

CDK4/6 Inhibitor Toxicity in HR+ Breast Cancer

March 29th 2019
CDK4/6 Inhibitors for HR+ Breast Cancer

CDK4/6 Inhibitors for HR+ Breast Cancer

March 29th 2019
Emerging Approaches for BRAF-Mutant Metastatic Melanoma

Emerging Approaches for BRAF-Mutant Metastatic Melanoma

March 28th 2019
Treatment Sequencing in BRAF+ Metastatic Melanoma

Treatment Sequencing in BRAF+ Metastatic Melanoma

March 28th 2019
Treatment Adherence and Response With BRAF-Targeted Therapy

Treatment Adherence and Response With BRAF-Targeted Therapy

March 28th 2019
BRAF/MEK Frontline Therapy in Metastatic Melanoma

BRAF/MEK Frontline Therapy in Metastatic Melanoma

March 28th 2019
Maximizing BRAF/MEK Inhibition in Melanoma

Maximizing BRAF/MEK Inhibition in Melanoma

March 28th 2019
Recommendations for Managing BRAF+ Metastatic Melanoma

Recommendations for Managing BRAF+ Metastatic Melanoma

March 28th 2019
BRAF-Targeted Therapy in Melanoma: Toxicity Management

BRAF-Targeted Therapy in Melanoma: Toxicity Management

March 28th 2019
Treating Melanoma Patients With BRAF/MEK Dual-Targeted Therapy

Treating Melanoma Patients With BRAF/MEK Dual-Targeted Therapy

March 28th 2019
The COLUMBUS Trial in BRAF-Mutant Melanoma

The COLUMBUS Trial in BRAF-Mutant Melanoma

March 28th 2019
BRAF/MEK Combinations Available in Advanced Melanoma

BRAF/MEK Combinations Available in Advanced Melanoma

March 28th 2019
BRAF/MEK Dual-Targeted Therapy in Advanced Melanoma

BRAF/MEK Dual-Targeted Therapy in Advanced Melanoma

March 28th 2019
Addressing Challenges With BRAF Inhibitors in Melanoma

Addressing Challenges With BRAF Inhibitors in Melanoma

March 28th 2019
BRAF as a Driver in Melanoma

BRAF as a Driver in Melanoma

March 28th 2019
Melanoma as an Oncogene-Addicted Cancer

Melanoma as an Oncogene-Addicted Cancer

March 28th 2019
Gene Mutations in Melanoma

Gene Mutations in Melanoma

March 28th 2019
Study Validates Speed, Accuracy of Liquid Biopsies Identifying NSCLC Biomarkers

Study Validates Speed, Accuracy of Liquid Biopsies Identifying NSCLC Biomarkers

February 28th 2019

A liquid biopsy test detected all of the guideline-recommended biomarkers in newly diagnosed patients with metastatic non–small cell lung cancer at a similar rate but faster turnaround time to that of tissue genotyping.

A Game-Changing Year for NSCLC

A Game-Changing Year for NSCLC

February 26th 2019
Available Therapies for ALK-Rearranged NSCLC

Available Therapies for ALK-Rearranged NSCLC

February 26th 2019
Resistance Mechanisms in EGFR+ NSCLC

Resistance Mechanisms in EGFR+ NSCLC

February 26th 2019
Osimertinib, the Standard for EGFR+ NSCLC

Osimertinib, the Standard for EGFR+ NSCLC

February 26th 2019
Molecular Testing for NSCLC in 2019

Molecular Testing for NSCLC in 2019

February 26th 2019
ADRIATIC Trial in Locally Advanced Small-Cell Lung Cancer

ADRIATIC Trial in Locally Advanced Small-Cell Lung Cancer

February 26th 2019
A Win for Small-Cell Lung Cancer: IMPOWER 133

A Win for Small-Cell Lung Cancer: IMPOWER 133

February 26th 2019
Treatment Options for mNSCLC After Progression

Treatment Options for mNSCLC After Progression

February 26th 2019
<1
...
363738394041424344
...
111>